×
About 11,935 results

ALLMedicine™ Irritable Bowel Syndrome Center

Research & Reviews  3,564 results

Alterations to microbial secretome by estrogen may contribute to sex bias in irritable ...
https://doi.org/10.1007/s10787-021-00906-8
Inflammopharmacology Pretorius L, Van Staden ADP et. al.

Jan 14th, 2022 - Irritable bowel syndrome (IBS) is a female predominant functional gastrointestinal disorder, underpinned by microbial dysbiosis and microinflammation. We suggest that changes in trace amine (TA) load and metabolism may link together diet, inflamma...

Zinc Deficiency and Intestinal Permeability in the Context of Rational Diagnostic and D...
https://doi.org/10.1007/s10620-021-07369-5 10.1053/j.gastro.2020.10.066 10.1053/j.gastro.2016.02.031 10.1136/gut.2006.099929 10.1136/gutjnl-2020-323026 10.1136/gutjnl-2019-318664 10.1136/gutjnl-2019-319281 10.1111/j.1365-2982.2009.01361.x
Digestive Diseases and Sciences; Shah ED

Jan 13th, 2022 - Zinc Deficiency and Intestinal Permeability in the Context of Rational Diagnostic and Drug Development for Diarrhea-Predominant Irritable Bowel Syndrome.|2022|Shah ED,|

Efficacy and Safety of Linaclotide in Patients with Irritable Bowel Syndrome with Const...
https://doi.org/10.1111/1751-2980.13081
Journal of Digestive Diseases; Peng L, Fang J et. al.

Jan 13th, 2022 - Linaclotide demonstrated potency in treating constipation-predominant irritable bowel syndrome (IBS-C), but few studies examined its use in Asian patients. Using data from a completed trial (NCT01880424), this sub-cohort analysis was performed to ...

QUALITATIVE VALIDATION OF A NOVEL VIRTUAL REALITY (VR) PROGRAM FOR IRRITABLE BOWEL SYND...
https://doi.org/10.14309/ajg.0000000000001641
The American Journal of Gastroenterology; Spiegel BMR, Liran O et. al.

Jan 13th, 2022 - Although gut-directed psychotherapies are effective for IBS, they are rarely prescribed given a paucity of trained clinicians. Virtual reality (VR) offers a solution by allowing patients to self-practice these techniques in a standardized manner. ...

Montelukast suppresses the development of irritable bowel syndrome phenotype possibly t...
https://doi.org/10.1007/s10787-021-00907-7 10.1016/j.ejphar.2021.174196 10.1016/j.drudis.2020.09.013
Inflammopharmacology Khodabakhsh P, Khoie N et. al.

Jan 12th, 2022 - Irritable bowel syndrome (IBS) is a functional gut disorder with multi-factorial pathophysiology that causes recurring pain or discomfort in the abdomen, as well as altered bowel habits. Montelukast, a well-known cysteinyl leukotriene receptor 1 (...

see more →

Guidelines  10 results

British Society of Gastroenterology guidelines on the management of irritable bowel syn...
https://doi.org/10.1136/gutjnl-2021-324598
Gut Vasant DH, Paine PA et. al.

Apr 28th, 2021 - Irritable bowel syndrome (IBS) remains one of the most common gastrointestinal disorders seen by clinicians in both primary and secondary care. Since publication of the last British Society of Gastroenterology (BSG) guideline in 2007, substantial ...

AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review.
https://doi.org/10.1053/j.gastro.2020.06.090
Gastroenterology Quigley EM, Murray JA et. al.

Jul 18th, 2020 - Thanks to ready access to hydrogen breath testing, small intestinal bacterial overgrowth is now commonly diagnosed among individuals presenting with a variety of gastrointestinal and even non-gastrointestinal complaints and is increasingly implica...

Canadian Association of Gastroenterology Clinical Practice Guideline on the Management ...
https://doi.org/10.1016/j.cgh.2019.08.062
Clinical Gastroenterology and Hepatology : the Official C... Sadowski DC, Camilleri M et. al.

Sep 19th, 2019 - Chronic diarrhea affects about 5% of the population overall. Altered bile acid metabolism is a common but frequently undiagnosed cause. We performed a systematic search of publication databases for studies of assessment and management of bile acid...

AGA Technical Review on the Evaluation of Functional Diarrhea and Diarrhea-Predominant ...
https://doi.org/10.1053/j.gastro.2019.06.014
Gastroenterology Carrasco-Labra A, Lytvyn L et. al.

Jul 29th, 2019 - The evaluation of patients with chronic watery diarrhea represents a diagnostic challenge for clinicians because organic causes, including inflammatory bowel disease, microscopic colitis, and chronic infection, must be differentiated from function...

AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea an...
https://doi.org/10.1053/j.gastro.2019.07.004
Gastroenterology Smalley W, Falck-Ytter C et. al.

Jul 16th, 2019 - AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D).|2019|Smalley W,Falck-Ytter C,Carrasco-Labra A,Wani S,Lytvyn L,|standards,diagnosis,etiology,p...

see more →

Drugs  239 results see all →

Clinicaltrials.gov  300 results

Open-Label Placebo Treatment of Women With Premenstrual Syndrome
https://clinicaltrials.gov/ct2/show/NCT03547661

Jan 12th, 2022 - Recent evidence suggests that in certain clinical conditions - such as chronic low-back pain, migraine, irritable bowel syndrome, attention deficit hyperactivity disorder, and rhinitis - placebos improve clinical outcomes even without deception. P...

A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)
https://clinicaltrials.gov/ct2/show/NCT04129619

Jan 11th, 2022 - The objectives of this study are to evaluate the efficacy, safety and tolerability of ORP-101 in patients with IBS-D. This is a randomized, double-blind, placebo-controlled, 3-arm, 12-week, parallel proof-of-concept study with 2 active arms (50 mg...

Developing Novel Microbiota-Targeted Therapies for Irritable Bowel Syndrome
https://clinicaltrials.gov/ct2/show/NCT02249169

Jan 5th, 2022 - This longitudinal study is being done to understand mechanisms underlying development of irritable bowel syndrome (IBS) and the role of the gut bacteria in development of symptoms. This information will be used to determine whether temporal change...

Exposure Therapy vs. Standardized Education for Distress Related to Somatic Symptoms
https://clinicaltrials.gov/ct2/show/NCT04942028

Jan 3rd, 2022 - Approximately one fifth of primary care patients seek care for symptoms that cannot readily be given a medical explanation. In addition, primary care is tasked with offering care for prevalent chronic diseases such as asthma and diabetes where som...

Gut Microbiota Reconstruction in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea
https://clinicaltrials.gov/ct2/show/NCT02651740

Dec 30th, 2021 - In this prospective study, there is only one group with no placebo/blank control. All qualified IBS-D patients could be admitted to hospital for at least one time of combing therapy (taking rifaximin for 3 days and then receiving fecal microbiota ...

see more →

News  590 results

Greater Intestinal Permeability Seen With Bile Acid Diarrhea Than IBS Diarrhea
https://www.medscape.com/viewarticle/965814

Jan 3rd, 2022 - NEW YORK (Reuters Health) - People with bile acid diarrhea (BAD) may have more permeable intestines than people with irritable bowel syndrome diarrhea (IBS-D), a new study suggests. "This study shows for the first time that patients with biochemic...

Microbiota May Predict Success on Low FODMAP Diet
https://www.medscape.com/viewarticle/964840

Dec 15th, 2021 - Two distinct gut microbiota subtypes showed an enhanced clinical response to a low FODMAP diet in an analysis of 41 adults with irritable bowel syndrome and household controls. Irritable bowel syndrome (IBS) has a significant impact on quality of ...

How to meet the challenges of managing patients with IBS
https://www.mdedge.com/familymedicine/article/248601/gastroenterology/how-meet-challenges-managing-patients-ibs
MDedge Family Medicine; Jose M. Villalon-Gomez, MD, MPH

Nov 12th, 2021 - Irritable bowel syndrome (IBS) continues to pose a diagnostic and therapeutic challenge to clinicians and patients—a challenge that arises from the varying manifestations of the condition, its complex pathophysiology, lack of effective treatment,.

Managing Pain in Gut-Brain Interaction Disorders
https://www.medscape.com/viewarticle/962796

Nov 11th, 2021 - An American Gastroenterological Association clinical practice update for gastrointestinal pain in disorders of gut-brain interaction (DGBI), published in Clinical Gastroenterology and Hepatology, emphasizes patient-physician collaboration and impr...

AGA Clinical Practice Update: Managing pain in gut-brain interaction disorders
https://www.mdedge.com/internalmedicine/article/248418/gastroenterology/aga-clinical-practice-update-managing-pain-gut
Jim Kling

Nov 8th, 2021 - An American Gastroenterological Association clinical practice update for gastrointestinal pain in disorders of gut-brain interaction (DGBI), published in Clinical Gastroenterology and Hepatology, emphasizes patient-physician collaboration and impr.

see more →

Patient Education  71 results see all →